Evaluating the Efficacy of Channa Striata in Stabilizing eNOS in Patients With Septic.
NCT05596942 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 42
Last updated 2022-10-27
Summary
Sepsis is an inflammation response produced by the host's immune system, which is agrravated by oxidative stress. One of the adjuvant therapy according to Surviving Sepsis Campaign Guideline is albumin, which has anti-inflammatory and anti-oxidant effects. However, human albumin is quite expensive, and other forms with similar potency and less costs are needed, one of which is Channa striata extract. Therefore, this study is conducted to compare albumin and human albumin, specifically their anti- inflammatory and anti-oxidant properties by assessing the eNOS marker, neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in patient with sepsis.
Conditions
Interventions
- DIETARY_SUPPLEMENT
-
Albumin Channa Striata Extract
This study is a randomized controlled trial of 42 patients at the ICU of Dr. Moewardi General Hospital. The control group received 20 grams of human albumin on the first day and the study group received 15 grams of Channa striata extract daily for two days. Subsequently, eNOS, NLR and PLR are measured before and three days after treatment, and the examiners compare the three markers statistically.
Sponsors & Collaborators
-
Universitas Sebelas Maret
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-07-01
- Primary Completion
- 2021-09-30
- Completion
- 2021-09-30
Countries
- Indonesia
Study Locations
More Related Trials
-
Treatment of ARDS With Sivelestat Sodium
NCT04909697 ·Status: COMPLETED ·Phase: PHASE4
-
The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration
NCT06994312 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study)
NCT02805049 ·Status: COMPLETED ·Phase: PHASE4
-
Mecobalamin Combined With Ceftriaxone Sodium in the Treatment of Sepsis Liver Injury
NCT06220929 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Effect of Statin Therapy on Mortality in Patients With Ventilator Associated Pneumonia
NCT05230472 ·Status: COMPLETED ·Phase: PHASE4
-
Serial Body Composition Change for Risk Prediction and Nutritional Guide in Treating Patients With Sepsis
NCT04989569 ·Status: COMPLETED ·Phase: NA
-
Effect of S-ketamine Anesthetic on Inflammatory Response in Septic Patients Undergoing Abdominal Surgery
NCT04873479 ·Status: UNKNOWN ·Phase: NA
-
Effect of Immunophenotype on Prognosis of Sepsis
NCT05602584 ·Status: UNKNOWN
-
Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis
NCT05634057 ·Status: RECRUITING ·Phase: NA
-
Resuscitation Failure, Oxidative Stress, and Necroptosis as Mortality Predictor in Septic Patient
NCT04169412 ·Status: COMPLETED
-
A Prospective Observational Study of Sepsis
NCT05309889 ·Status: UNKNOWN
-
The Effect of Semi-quantitative Procalcitonin Assay to The Adequacy of Empirical Antibiotics and Mortality in Septic Patients
NCT01862185 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Effects of Sivelestat Sodium on Improving ARDS in Patients With COVID-19
NCT06218862 ·Status: COMPLETED
-
Statins for the Early Treatment of Sepsis
NCT00528580 ·Status: TERMINATED ·Phase: PHASE2
-
Identification of Cardiovascular and Molecular Prognostic Factors for the Mid- and Long-term Outcome of Sepsis
NCT03620409 ·Status: COMPLETED
-
Selenium, as Sodium Selenite, in the Treatment of Septic Shock
NCT00207844 ·Status: COMPLETED ·Phase: PHASE2
-
Erythromycin in Septic Patients: Immunomodulatory Role and Clinical Impact
NCT04665089 ·Status: COMPLETED ·Phase: NA
-
Alpha-Lipoic Acid in Patients With Sepsis
NCT05808946 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Early Administration of Norepinephrine in Sepsis
NCT05836272 ·Status: RECRUITING ·Phase: PHASE4
-
Prolonged Intravenous Infusion of β-lactam Antibiotics in Early Septic Patients
NCT05024565 ·Status: UNKNOWN ·Phase: NA
-
Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis
NCT04910464 ·Status: RECRUITING ·Phase: PHASE3
-
We Collected Blood Samples From Septic Shock Patients and Measured ELABELA, Creatinine, and NGAL Levels. Survival After 7 Days Was Recorded and Analyzed to Evaluate the Potential of Serum ELABELA as an Early Diagnostic Marker for Sepsis-associated Acute Kidney Injury.
NCT06001294 ·Status: UNKNOWN
-
Efficacy and Safety of Electroacupuncture for ICU Sepsis Patients
NCT06666946 ·Status: RECRUITING ·Phase: NA
-
Albumin Infusion Targets on Mortality in Patients With Abdominal Sepsis
NCT06874634 ·Status: COMPLETED
-
Effects of Enteral Nutrition Content on Disease Progression in Sepsis Patients
NCT06943326 ·Status: RECRUITING